Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Director | April 23, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date April 23, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 516,740 |
Reported balance
After 2026-04-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-23 · Purchase · Acquired 508,614 · Balance 516,740 F1: The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 916,740 |
Reported balance
After 2026-08-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-07 · Purchase · Acquired 400,000 · Balance 916,740 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2028-04-23 | Direct | 289,836 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Conversion · Acquired 254,307 · Balance 289,836 F2: Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169. |
Filing footnotes · ownership attribution and instrument terms
F1: The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person.
F2: Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RENOVARE ENVIRONMENTAL, INC.
Report date November 14, 2017 · Filed July 20, 2018
Section 16 reporting ended · disclosed 2018-07-20. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 18, 2026 10:06 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 400,000 | $0.50 | $198,000.00 |
DisclosureSEC source: 0001493152-26-038866 · ownership.xml · nonDerivative · entry 2 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 916,740 Read SEC document |
| April 23, 2026 Filed Aug 18, 2026 10:06 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | ConversionWarrant · Derivative | 254,307 | Not disclosed Strike: $0.48 | Not disclosed |
DisclosureSEC source: 0001493152-26-038866 · ownership.xml · derivative · entry 3 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,836 Underlying: Common Stock · 254,307 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169. Read SEC document |
| April 23, 2026 Filed Aug 18, 2026 10:06 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 508,614 | $0.48 | $246,169.18 |
DisclosureSEC source: 0001493152-26-038866 · ownership.xml · nonDerivative · entry 1 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,740 F1 · balance_after: The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:33 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 90,287 | $0.49 | $44,087.14 |
DisclosureSEC source: 0001493152-23-006786 · ownership.xml · nonDerivative · entry 1 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,682 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 20:45 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 270,000 | $0.48 | $128,979.00 |
DisclosureSEC source: 0001493152-23-006553 · ownership.xml · nonDerivative · entry 2 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,395 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 20:45 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 109,300 | $0.49 | $53,371.19 |
DisclosureSEC source: 0001493152-23-006553 · ownership.xml · nonDerivative · entry 1 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,395 Read SEC document |
| December 09, 2022 Filed Feb 1, 2023 23:06 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantWarrants · Derivative | 714,286 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001493152-23-003343 · ownership.xml · derivative · entry 2 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,365 Underlying: Common Stock · 714,286 shares Expires 2027-12-09 F1 · security: On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock"). F3 · security: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance. F3 · price: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance. F3 · derivative.exercise_date: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance. F3 · balance_after: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance. Read SEC document |
| December 09, 2022 Filed Feb 1, 2023 23:06 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 357,143 | $1.40 | $500,000.20 |
DisclosureSEC source: 0001493152-23-003343 · ownership.xml · nonDerivative · entry 1 GOWER BOB G · CIK 0001136466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,095 F1 · security: On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock"). F2 · security: On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share. F2 · balance_after: On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 21:40 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 15,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001493152-22-017876 · ownership.xml · derivative · entry 2 GOWER BOB G · CIK 0001136466 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,585 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · security: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · price: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · derivative.exercise_date: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. Read SEC document |
| February 04, 2022 Filed Feb 4, 2022 20:18 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001493152-22-003208 · ownership.xml · derivative · entry 1 GOWER BOB G · CIK 0001136466 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-04 F1 · security: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. F1 · price: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. F1 · derivative.exercise_date: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:15 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 6,585 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001192482-21-000620 · edgar.xml · derivative · entry 2 GOWER BOB G · CIK 0001136466 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 Underlying: Common Stock · 6,585 shares Expires 2029-03-14 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:15 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantCommon Stock | 7,919,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000620 · edgar.xml · nonDerivative · entry 1 GOWER BOB G · CIK 0001136466 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,919,026 F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.